STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

GHRH analogs (clinic-compounded class discussion)

Also known as

Tesamorelin class discussion · compounded GHRH · GHRH blends · GHRH analogs · Egrifta (brand reference) · tesamorelin research discussion · tesamorelin vs sermorelin vs CJC · GHRH peptide class · growth hormone releasing hormone analogs · clinic GHRH stack talk

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic SubQ Growth hormone axis

Systemic — pituitary GHRH-receptor stimulation → endogenous GH pulses → hepatic IGF-1 and whole-body composition effects.

What people say This is a comparison card for GHRH analogs, not one interchangeable drug. Tesamorelin has HIV-lipodystrophy VAT data; sermorelin and CJC forms have different evidence, doses and kinetics. Doses people talk about
Tesamorelin trial and community context~1–2 mg SubQ once daily

Older HIV VAT programs used about 2 mg daily; current EGRIFTA SV labeling is formulation-specific and uses 1.4 mg daily.

Sermorelin wellness-chart band~100–500 mcg SubQ nightly

The notes describe low-hundreds-of-microgram adult wellness charts; evidence and product identity differ from tesamorelin.

CJC no-DAC pulse discussion~100–300 mcg SubQ per injection, 1–3× daily

Usually discussed with a GHRP. This short-form schedule must not be copied to CJC with DAC.

CJC with DAC discussion~1–2 mg SubQ once or twice weekly

The albumin-binding form has a separate multi-day schedule and identity-risk warning.

These are separate compounds and formulations, not a dose ladder. Vendor blends can make total vial mass differ from each component amount.

Half-life & effect duration

Half-life in the body
  • Tesamorelin · Egrifta SVAbout 8 minutes
  • Tesamorelin · Egrifta WRAbout 11 minutes
  • Tesamorelin · older repeated-dose reportsAbout 26–38 minutes
  • Sermorelin · historical IV studyAbout 6–7 minutes
  • Sermorelin · community / clinic estimatesAbout 10–12 minutes; broader reports 10–20 minutes
  • No-DAC CJC / Mod GRF · community estimatesAbout 25–30 minutes; other guides give 1–2 hours
  • CJC with DACAbout 6–8 days
Felt duration people report
  • Sleep / body-change reportsMixed sleep and water-retention experiences
  • During coursesLittle change at 5 weeks, claimed results at 8–14 weeks, or limited results after months
Timing context & sources
How it may feel Often there is little immediate buzz. Reports range from sleep or recovery changes and water retention to mild or absent body-composition change, with visible timing described from weeks to months.
Cycles people discuss Tesamorelin trials used continuous daily months-long blocks; sermorelin and CJC/Ipamorelin discussions use different multi-month and on/off calendars. Those schedules are not class-wide PK rules. Timing Morning and pre-bed use both appear, often placed away from food in forum culture. That preference does not create one class half-life: tesamorelin, short GRF and DAC forms differ sharply. Stacks GHRH plus Ipamorelin is the dominant combination talk, while GLP-1s, MOTS-c and recovery peptides appear in wider stacks. Mixed use makes sleep, fat and side-effect attribution difficult. Watch for Glucose / diabetes risk: Tesamorelin can worsen glycemic control; label/trial language includes higher risk of new diabetes vs placebo and glucose monitoring themes — careful clinics watch fasting glucose/HbA1c, especially with prediabetes or multi-peptide stacks.
Related
TesamorelinSermorelinCJC-1295IpamorelinGHRP-2

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

There is no single class half-life; EGRIFTA SV tesamorelin is one measured example at about 8 minutes.

The official label measured an 8-minute mean elimination half-life after one 1.4 mg SubQ EGRIFTA SV dose in healthy subjects. The card also covers sermorelin, CJC no-DAC and CJC with DAC, whose values cannot inherit that result.

The 8-minute product-specific result is not a class range and does not establish the kinetics of compounded blends, different formulations or DAC-bound peptides.

  • DailyMed: EGRIFTA SV full prescribing information (opens in a new tab)Sections 2.1 and 12.3: formulation-specific 1.4 mg SubQ daily labeling; PK in healthy and HIV-infected subjects; 0.15-hour median Tmax and 8-minute mean elimination half-life after one 1.4 mg EGRIFTA SV dose. Full page inspected.Official data apply to named tesamorelin formulations, not to sermorelin, CJC forms or compounded class blends.

Felt duration people report

No dependable per-dose felt window; forum reports disagree on sleep, water retention and when body-composition changes appear.

A reviewed thread included little change at five weeks, claimed results at eight or fourteen weeks, only four pounds after eight months, and mixed morning versus bedtime use. Several accounts also used retatrutide, Ipamorelin, diet or exercise.

Multiple compounds, self-selected reporters, unverified products and co-exposures prevent a class-wide onset or felt-duration range.

  • Tesamorelin for belly fat with about five weeks until vacation? (opens in a new tab)Read the complete visible thread and follow-ups: conflicting reports at roughly 5, 8, 12, 14 weeks and 8 months; morning versus bedtime use; one claimed +150 IGF change; water-retention discussion; and co-use of retatrutide, Ipamorelin, diet and exercise.Multiple authors, unverified compounds and strong co-exposure confounding; replies mix visceral fat with visible waist and subcutaneous-fat claims, so no prevalence or causal timing is inferred.

What people say 17

  • Clinic / recomp claims (class): Compounded tesamorelin and GHRH blends marketed for stubborn midsection, lean retention on cuts, recovery, and “GH look” without full HGH cost — non-HIV evidence is thin and stack-confounded. forum
  • Sermorelin sleep/recovery lane: Bedtime sermorelin logs emphasize deeper sleep and next-day recovery more than dramatic VAT imaging; solo attribution often muddied by +Ipamorelin. forum
  • CJC/Ipa composition lane: Dual-pathway short GHRH + selective GHS is the high-volume “general GH optimization” stack when clinics position tesa as VAT-specific and CJC/Ipa as sleep/recovery/skin. forum
  • Vs MK-677: Injectable timed GHRH pulses vs oral daily ghrelin-mimetic with hunger, water, and more continuous GH-tone talk. forum
  • Vs HGH: Endogenous pulse culture vs flat IU somatropin; many prefer class members when they want VAT branding or lower cost than multi-IU HGH — results and sides both typically milder than high-dose rGH stories. forum
  • Budget substitute narrative: When branded or compounded tesa is expensive, users swap to Mod GRF 1–29 / CJC no-DAC + Ipamorelin and accept weaker formal VAT data. forum
  • Stack confounder: Midsection “wins” often co-run diet, lifting, GLP-1s, Ipamorelin, MOTS-c, or alcohol cuts — individual peptide credit is unreliable. forum
  • VAT (tesamorelin pivotal): HIV Phase 3 programs — roughly ~15% VAT reduction vs placebo rise/flat over ~26 weeks at ~2 mg SC daily (e.g., Falutz NEJM-style: ~15% down vs ~5% placebo up; other summaries cite treatment differences on the order of ~−12% to −20%). trial
  • VAT maintenance / extension: Continued therapy toward ~52 weeks held VAT loss near ~18% from baseline in extension summaries; switching to placebo after 26 weeks was associated with reaccumulation. trial
  • VAT selectivity: Imaging studies emphasize visceral adipose drop with limited subcutaneous-fat change — scale weight can look almost flat while CT/MRI VAT improves. trial
  • Trunk fat / waist: Trial language includes trunk-fat reduction and modest waist-circumference improvements (often summarized ~2–3 cm vs placebo; some responder analyses ~3–4+ cm). trial
  • Lean mass: Label/FDA-style summaries describe roughly ~1–1.5 kg lean gain with near-matching fat-mass loss in HIV programs — recomp signal, not steroid bulk. trial
  • IGF-1 rise: Mean IGF-I increases mark GH stimulation (example: ~81% rise in a key HIV study arm; extension data with large absolute ng/mL lifts and many patients above upper SDS). trial
  • Lipids: Mixed but positive signals in HIV work — triglycerides and total/HDL ratio improvements in pivotal reporting; not guaranteed in off-label gym use. trial
  • Liver fat (HIV NAFLD): Stanley et al. Lancet HIV 2019 — 2 mg daily ~12 months reduced hepatic fat fraction (absolute effect size about −4.1%; ~37% relative reduction) vs placebo; ~35% vs ~4% reached HFF <5%. trial
  • Appearance distress: Some HIV trials improved belly-appearance distress scores alongside VAT loss. trial
  • Responders frame: Post-hoc talk often uses ≥8% VAT drop as a “responder” cut; responders who continued could maintain benefit out toward 52 weeks. trial

Doses people talk about 22

  • Tesamorelin — community / compounded band: Dominant discussed range is 1–2 mg daily SC; 2 mg treated as “match the data,” 1 mg as start, tolerance, cost, or stack titration. forum
  • Tesamorelin — above 2 mg: No meaningful published efficacy culture for routine >2 mg daily; escalation past studied exposure is widely called unjustified risk. forum
  • Tesamorelin — split-dose minority: Some stack charts mention splitting 1–2 mg (e.g., AM + pre-bed); bedtime-only remains the recomp default. forum
  • Tesamorelin — not mcg GHRP math: Do not copy CJC/Ipamorelin 100–300 mcg charts onto a mg-class tesa vial. forum
  • Sermorelin — modal adult band: ~200–300 mcg once nightly SC is the most repeated wellness “standard.” forum
  • Sermorelin — start / upper bands: Starts often ~100–200 mcg nightly; upper charts reach ~400–500 mcg nightly when response is “not enough” — somatostatin saturation lore argues against mega-dosing. forum
  • Sermorelin — wide clinic range: ~100–500 mcg daily bedtime SC covers nearly all adult wellness charts surveyed. forum
  • Sermorelin — 5-on/2-off: Very common clinic schedule (weekday pins, weekend off) for cost/compliance and pituitary-rest folklore; continuous 7-night also used. forum
  • Sermorelin + Ipamorelin templates: Discussed pairings include ~250–300 mcg sermorelin + ~200–300 mcg ipamorelin same night, or equal ~100/100–200/200 draws; premixed troches/vials (e.g., 300/200 mcg style marketing) are compounder-specific. forum
  • CJC-1295 no DAC (Mod GRF 1–29) — pulse culture: Commonly ~100–300 mcg per injection, often 1–3× daily, almost always co-timed with a GHRP when used for recomp/sleep. forum
  • CJC no DAC + Ipamorelin — classic starter: ~100 mcg CJC + ~100 mcg Ipamorelin (“100/100”) per shot; optimized lore often shifts IPA-heavy to ~100 mcg CJC + 200–300 mcg Ipamorelin. forum
  • Premixed blend math: Vendor “CJC/IPA 5 mg + 5 mg” style vials make unit math for total blend ≠ per-peptide mcg; ratios and fill accuracy vary — recompute from label. forum
  • Class comparison table (discussion only): Tesa ≈ mg daily VAT branding; sermorelin ≈ low-hundreds mcg nightly sleep/longevity; CJC no DAC ≈ 100–300 mcg multi-pulse with GHRP; CJC DAC ≈ mg-scale multi-day. forum
  • Uncertainty: Compounded/research identity, underfill, counterfeit risk, and concentration errors mean labeled dose ≠ delivered peptide. forum
  • Tesamorelin — titration lore: Common forum advice: start ~1 mg for ~1–2 weeks, then move to ~2 mg if water/joint/glucose feel stays manageable — not a published titration RCT for aesthetics. forum
  • Tesamorelin — daily vs 5-on/2-off: All pivotal trials were continuous daily. 5 days on / 2 off (or 6/1) is widespread for cost, lifestyle, or “receptor rest” folklore; critics note IGF-1 drifts on off days and VAT data was built on uninterrupted daily exposure. forumtrial
  • Tesamorelin — timing / fasted culture: Recomp forums discuss both pre-bed and morning SubQ use, commonly placed away from food because users believe insulin can blunt GH release. In one reviewed thread, a morning user chose that clock because a two-hour pre-bed fast was impractical; these schedules are community preferences, while the label centers on same-time daily abdominal dosing rather than a fasting rule. forumtrial
  • CJC-1295 with DAC — different schedule: Multi-day half-life culture → roughly 1–2 mg once or twice weekly (or historical mcg/kg trial bands), not daily 100 mcg co-injection with Ipamorelin. Mislabeling DAC vs no-DAC is a major forum failure mode. forumtrial
  • CJC no DAC — saturation lore: Forum lore often treats ~100 mcg (sometimes ~1 mcg/kg framing) as near-max useful pulse for the short GHRH analog — pushing far above is called waste. forum
  • Framing: Clinic, label, trial, and forum ranges only — research/educational discussion, not advice or prescriptions. Compounded and research-chem identity, concentration, and sterility vary. forum
  • Tesamorelin — original trial / early label: ~2 mg subcutaneous once daily (Phase 3 HIV VAT programs; early Egrifta 1 mg/vial era often two vials per dose). trial
  • Tesamorelin — dose-finding note: Early HIV work comparing 1 mg vs 2 mg SC favored the higher dose for VAT (example small-study framing ~−16% at 2 mg vs ~−4% at 1 mg over ~12 weeks); IGF-1 was higher at 2 mg than 1 mg. trial

How it may feel 8

  • Minutes–hours post-shot: Usually little systemic “buzz”; minority report injection-site sting, brief flush (classic with sermorelin lore), or same-night water/joint tightness. forum
  • Days 1–7: Habit formation and early sides (edema, joint ache, sleep shift) dominate — not visible fat change. forum
  • Days 1–14 (tesa-heavy protocols): Often little subjective change; site irritation or mild water retention possible. forum
  • Weeks 1–2: IGF-1 already rising in trial math for daily tesa; sleep anecdotes more common for bedtime sermorelin or CJC/Ipa than for tesa alone. trialforum
  • Weeks 2–4: Common first IGF-1 / glucose lab check in clinic talk; energy reports inconsistent; early belt-notch claims are anecdote-level. forum
  • Weeks 3–4: Some recomp logs claim subtle clothing fit; still far short of 26-week VAT imaging windows. anecdote
  • Weeks 5–14 and beyond: In one reviewed discussion, posters reported no visible change around five weeks, noticeable results after eight weeks, a claimed two-inch change only around week 14, and only four pounds lost after eight months; several emphasized that visceral fat is not the same as pinchable lower-belly fat. forum
  • ~12–26 weeks: Matches pivotal tesa VAT window; most serious before/after and clinic reassessments cluster here. trial

Cycles people discuss 12

  • Tesamorelin clinic / open-ended style: Often multi-month or open-ended daily use with periodic IGF-1 and metabolic labs rather than classic on/off steroid cycles. forum
  • Tesamorelin short aesthetic pulses: Some try ~8–16 week recomp blocks — anecdote length, shorter than full trial VAT windows. anecdote
  • CJC/Ipa cycles: Multi-month runs with scheduled offs (examples discussed: ~8–12 weeks on / ~4 off, or 3-on/1-off style templates) appear often; continuous year-round use is less carefully logged. forum
  • Time-off rationales (class): High IGF-1, glucose worsening, edema/CTS, cost, planned diet breaks, or “desensitization” folklore — not a standardized SERM-style PCT. forum
  • 5-on/2-off across the class: Convenience and cost driver for tesa, sermorelin, and some stacks; evidence superiority over daily continuous is absent for VAT endpoints. forum
  • Women / non-HIV populations: Off-label and research-chem discussion exists; large long-term body-comp RCTs in healthy athletes are sparse — do not map HIV trial risk/benefit 1:1. forum
  • Monitoring theme: Longer use paired with IGF-1, fasting glucose/HbA1c, waist/VAT-aware photos, and clinical side review rather than blind mg/mcg escalation. trialforum
  • Tesamorelin trial main block: ~26 weeks continuous daily use for primary VAT endpoints in HIV Phase 3 programs. trial
  • Tesamorelin trial extension: Additional ~26 weeks (to ~52 weeks total) for maintenance on continued therapy vs rebound when switched to placebo. trial
  • Tesamorelin NAFLD block: Stanley HIV NAFLD RCT used ~12 months continuous 2 mg daily for hepatic fat fraction. trial
  • Tesamorelin stop = regain: VAT reaccumulation after discontinuation is a documented trial pattern; serious writeups treat ongoing therapy or repeated courses, not a permanent “one blast.” trial
  • Sermorelin cycles: Clinic pages commonly describe ~3–6 month courses; some continue indefinitely under supervision for sleep/anti-aging framing; 5-on/2-off soft cycling inside those blocks is common. forum

Timing 13

  • CJC no DAC / Mod GRF 1–29: Community/research half-life talk ~25–30 minutes to under an hour → multi-pulse daily culture when users want several GH spikes. forumtrial
  • CJC with DAC: Albumin-binding design → multi-day half-life (forum/clinic talk often ~6–8 days) → weekly or twice-weekly pins and more continuous GH/IGF-1 elevation vs pure pulse culture. forumtrial
  • Food / insulin blunting (class-wide lore): Empty-stomach timing is nearly universal in recomp/secretagogue culture — carbs/insulin near the dose believed to blunt GH release. forum
  • Sleep coupling: Pre-bed dosing aims to ride the large nocturnal GH pulse rather than fight daytime food and cortisol context. forum
  • Somatostatin feedback: Axis still caps runaway GH — more peptide is not linear “more gains”; used as the bro explanation against mega-dosing solo GHRH. forum
  • Tesamorelin plasma half-life (short): Literature/secondary writeups commonly cite ~26–38 minutes after repeated SC dosing; FDA clinical pharmacology also reports shorter single-dose elimination figures ~8–13 minutes (dose/context dependent) and multi-dose SC means rising into ~18–38 minutes. Label language for Egrifta SV-class includes ~8 minutes after single 1.4 mg SC in healthy subjects. trial
  • Tesamorelin vs native GHRH: Native GHRH degrades in minutes (often cited <7 min); the hexenoyl modification extends usable stimulus enough for once-daily SC practice. trial
  • Tesamorelin Tmax / GH pulse: Peptide levels often peak ~30 minutes post-SC; downstream GH activity is described on the order of ~1–2 hours then baseline — not a multi-day depot. trial
  • Tesamorelin no accumulation: PK summaries report no meaningful multi-dose accumulation — supports daily redosing rather than build-up. trial
  • Sermorelin half-life: Plasma half-life often cited ~10–12 minutes (ranges ~10–20 min; older IV work shorter) → nightly dosing aimed at the nocturnal GH window. trial
  • Why daily for tesa/sermorelin: Short GHRH stimulus → once-daily SC is the studied or clinic-default rhythm; unlike DAC forms, there is no weekly pin culture for pure tesamorelin. trial
  • IGF-1 lag: Acute GH pulses vs multi-week IGF-1 elevation used as both efficacy and overstimulation safety marker. trial
  • After last dose: GH/IGF-1 drift toward baseline over days–weeks; composition reverse (especially VAT after tesa stop) is measured over months. trial

More on what it is 9

  • Why this card exists: Forums, telehealth clinics, and research-chem vendors treat tesamorelin, sermorelin (GHRH 1–29 / GRF 1–29), CJC-1295 (no DAC / Mod GRF 1–29), CJC-1295 with DAC, and premixed GHRH+GHRP blends as one shopping class even though half-lives, doses (mg vs mcg), and evidence bases differ sharply. forum
  • Sermorelin lane: Shorter GHRH(1–29) fragment; historical Geref brand for pediatric GHD; modern adult wellness use is mostly compounded nightly low-hundreds-of-mcg protocols for sleep/recovery/anti-aging talk. trialforum
  • CJC lane: CJC-1295 without DAC (Mod GRF 1–29) is short-acting and usually co-timed with a GHRP (especially Ipamorelin); CJC with DAC uses Drug Affinity Complex albumin binding for multi-day GH/IGF-1 elevation and less-frequent pins. forumtrial
  • Vs rhGH: Class pitch is “stimulate native pulsatile GH with somatostatin still capping the axis,” not inject flat exogenous GH — still systemic IGF-1 and GH-pathway sides. trialforum
  • Vs GHRPs alone: GHRH analogs are not 1:1 swaps for Ipamorelin / GHRP-2 / GHRP-6 (ghrelin-receptor agonists); the highest-volume culture stacks GHRH + GHRP for “amplifier + trigger.” forum
  • Evidence honesty: Strong Phase 3 RCTs for branded tesamorelin VAT endpoints in HIV; sermorelin and CJC/Ipa wellness/recomp use is mostly small older GHRH work, PK studies, clinic marketing, and forum logs — not interchangeable evidence. trialforum
  • Class: Synthetic growth-hormone-releasing hormone (GHRH) analogs that bind pituitary GHRH receptors and raise your own GH pulses — not recombinant somatropin itself. trial
  • Anchor molecule: Tesamorelin (TH9507 / Egrifta family) is a ~44-aa GHRH analog with an N-terminal trans-3-hexenoyl modification for DPP-IV resistance; it is the best-documented member (FDA-approved for excess abdominal visceral fat in HIV-associated lipodystrophy). trial
  • Not: Not a fat-burner stimulant, not a steroid/SARM, not a GLP-1, not an oral peptide with Egrifta-class data, not a permanent VAT cure after stop. trial

Stacks 12

  • GHRH + GHRP (class default): Tesamorelin or CJC or sermorelin + Ipamorelin (or older GHRP-2/6) = top dual-pathway “GH pulse” stack — confounds credit and can amplify water/joint/IGF-1 sides. forum
  • Tesamorelin + Ipamorelin: Highest-volume tesa dual stack; community examples include 2 mg tesa + 200–300 mcg ipa pre-bed, or 1 mg tesa + 200–300 mcg ipa, sometimes 5–6 nights/week; clinic marketing may use unit-based combined draws that are recon-specific. forum
  • Tesamorelin + CJC/Ipa layering: Wellness “full GH-axis” — tesa positioned for VAT, CJC/Ipa for recovery/sleep; heavy confounding and higher stimulation burden. forum
  • CJC no DAC + Ipamorelin alone: Premixed or co-drawn daily/multi-pulse culture framed as cheaper general alternative when tesa cost or access is brutal. forum
  • Sermorelin + Ipamorelin: Longevity-clinic dual stack for sleep/recovery with gentler branding than tesa. forum
  • Tesamorelin + sermorelin (minority): Occasional “two GHRH” talk (e.g., different times of day); other clinicians call dual pure-GHRH non-standard and riskier for supraphysiologic GH/IGF-1. forum
  • + GLP-1 / dual / triple agonists: Frequently stacked with semaglutide, tirzepatide, or retatrutide — GLP-1 drives appetite/total fat while tesa is sold as VAT polish; highly confounded. forum
  • + MOTS-c: Appears in metabolic “cheat sheet” stacks with reta + tesa; preclinical/community adjacency more than a joint RCT. forum
  • Fat-loss adjacency: Talk next to AOD-9604 / Frag 176-191 or deficit training — attribution muddy. forum
  • Recovery adjacency: Occasional BPC-157 / TB-500 co-talk when joint comfort is already an issue on GH-axis drugs — separate mechanisms. forum
  • Avoid redundant HGH stack (common caution): Running GHRH analogs + high-dose exogenous HGH often called unnecessary same-axis overload with stacked edema/glucose/IGF-1 risk. forum
  • Lifestyle co-factors: Sleep, lifting, protein, and a real calorie plan are repeatedly credited when composition looks good — peptide-only miracles are rare in logs. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Injection site (class-wide, strongest for tesa trials): Redness, itch, pain, swelling, bruise, irritation — among the most common AEs in Egrifta programs and user logs; rotate sites. trialforum
  • Carpal tunnel / paresthesia: Numbness, tingling, CTS-like symptoms when stimulation or fluid is aggressive — label and community both flag. trialforum
  • IGF-1 / malignancy caution: Marked IGF-1 rise is expected on effective GHRH stimulation; high IGF-1 fuels active-malignancy and cancer-history debate in labeling and forums — caution theme, not a full personalized risk table here. trialforum
  • Sermorelin-specific lore: Brief facial flush minutes after the shot is classic and often short-lived; headache and site reaction also common in wellness writeups. forum
  • CJC DAC continuous-tone lore: Some prefer no-DAC pulses over DAC because multi-day elevation is framed as less “physiologic” and more side-prone — preference lore more than a head-to-head aesthetic RCT. forum
  • GHRP stack sides: Adding GHRP-6 hunger, GHRP-2 cortisol/prolactin lore, or high-dose Ipamorelin can change the side picture beyond pure GHRH. forum
  • WADA / sport: Growth-hormone releasing factors are prohibited in competitive sport — sanction risk is real for tested athletes. forum
  • Source / product risk: Non-branded identity, potency, sterility, underfill, DAC vs no-DAC mislabel, and unit-math errors are major practical risks. forum
  • Stack amplification: GHRPs, MK-677, or HGH on top of GHRH analogs can stack water, glucose, and IGF-1 burden — more is not automatically better VAT loss. forum
  • Edema / fluid retention: Peripheral edema, puffy hands/ankles/face — classic GH-pathway water side across the class; may drive dose cut or pause. trial
  • Arthralgia / myalgia: Joint and muscle pain appear in labeled tesamorelin safety and in secretagogue logs; common discontinuation driver. trial
  • Glucose / diabetes risk: Tesamorelin can worsen glycemic control; label/trial language includes higher risk of new diabetes vs placebo and glucose monitoring themes — careful clinics watch fasting glucose/HbA1c, especially with prediabetes or multi-peptide stacks. trial
  • Hypersensitivity: Hypersensitivity reactions and rare serious events appear in tesamorelin program safety language. trial
  • Not general weight-loss: Tesamorelin is not approved for general obesity; subcutaneous fat and scale may barely move even when VAT imaging improves. trial
  • Rebound after stop: VAT (and related midsection gains) can reverse after discontinuation — plan for lifestyle maintenance or expect reaccumulation talk. trial
  • Label contraindication themes (tesa): Active malignancy, disruption of hypothalamic-pituitary axis, pregnancy, known hypersensitivity; extra caution clusters include diabetes, carpal tunnel, edema, and related clinical histories. trial
  • Never risk-free: Approved tesamorelin has labeled AEs; research-chem and compounded class use adds product-quality and off-label population unknowns. Research-only / educational framing only. trialforum

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →